Andrew Haydon Clinical Oncology Society of Australia Annual Scientific Meeting 2021

Abstracts this author is presenting:

• Five-year overall survival (OS) in COLUMBUS: A randomized phase 3 trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients (pts) with BRAF V600-mutant melanoma. — e-Poster Listing